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Background: We undertook genetic analysis of three affected families to identify the cause of dominantly-inherited
CAPOS (cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss) syndrome.
Methods: We used whole-exome sequencing to analyze two families affected with CAPOS syndrome, including the
original family reported in 1996, and Sanger sequencing to assess familial segregation of rare variants identified in
the probands and in a third, apparently unrelated family with CAPOS syndrome.
Results: We found an identical heterozygous missense mutation, c.2452G > A (p.(Glu818Lys)), in the Na+/K+ ATPase
α3 (ATP1A3) gene in the proband and his affected sister and mother, but not in either unaffected maternal
grandparent, in the first family. The same mutation was also identified in the proband and three other affected
members of the second family and in all three affected members of the third family. This mutation was not found
in more than 3600 chromosomes from unaffected individuals.
Conclusion: Other mutations in ATP1A3 have previously been demonstrated to cause rapid-onset dystonia-parkinsonism
(also called dystonia-12) or alternating hemiplegia of childhood. This study shows that an allelic mutation in ATP1A3
produces CAPOS syndrome.
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Cerebellar ataxia, areflexia, pes cavus, optic atrophy, and
sensorineural hearing loss (CAPOS) syndrome (OMIM
601338) is a rare neurological disorder, which to date has
only been reported in a single family. In 1996, Nicolaides
et al. [1] described CAPOS syndrome in a brother and
sister and their mother, all of whom were normal until they
presented with a relapsing and partially remitting, early-
onset cerebellar ataxia following a febrile illness. Other fea-
tures included progressive optic atrophy and sensorineural
hearing loss, generalized hypotonia, areflexia and pes cavus
without evidence of a peripheral neuropathy on neuro-
physiological studies. All three patients shared these key* Correspondence: mdemos@cw.bc.ca; jan.friedman@ubc.ca
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stated.features, although the severity and number of ataxic
relapses varied. The mode of inheritance was thought to be
autosomal dominant or mitochondrial. Extensive investiga-
tions failed to identify a cause, and the authors believed
that the neurological disorder affecting this family probably
represented a “new” “ataxia plus” syndrome. No other
patients with CAPOS syndrome have been reported in the
subsequent 17 years.
We have identified two additional families with CAPOS
syndrome and reassessed the original family. We here
describe the clinical features and natural history of this
disorder and report a novel heterozygous missense muta-
tion of the ATP1A3 gene that causes CAPOS syndrome
in all ten affected members of these three apparently
unrelated families.Methods
We obtained informed consent and assent, when appro-
priate, from participating family members. Ethical reviewLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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GEnes (FORGE) Canada Consortium and University of
British Columbia were also obtained. Clinical details of
Family 1, originally described in 1996 [1], were updated
by A.F. in 2013.
We performed whole exome sequencing on DNA from
the probands in Families 1 (Figure 1A, Family 1 III-1)Figure 1 Pedigrees and Sanger sequencing results in three families w
Nicolaides et al. [1] Individuals with CAPOS syndrome are indicated by filled
B) Sanger sequencing results in affected and unaffected family members. A
who was tested, with the nucleotides at Ch19:47,166,267, corresponding to
blue line. Each affected individual is heterozygous for the variant T (corresp
nucleotides. C) Conservation of Na+/K+ ATPase α3 protein sequence in the
families is shown in red type; the location of the E815K loss-of-function mu
shown in blue type. This segment of the Na+/K+ ATPase α3 protein is highland 2 (Figure 1A, Family 2 II-2) on an Illumina HiSeq
2000 after SureSelect Target enrichment with an Agilent
50 Mb Human All Exon Kit (Agilent Technologies Inc.,
USA) using the manufacturers’ protocols and other
methods previously described [2]. Illumina's GA Pipeline
was used to remove sequencing reads that failed chastity
filtering, and the remaining reads were mapped to theith CAPOS syndrome. A) Pedigees. Family 1 was initially described by
pedigree symbols, and unaffected individuals, by empty symbols.
portion of the Sanger sequencing trace is shown for each individual
ATP1A3 position c.2452 on the minus strand, indicated by a vertical
onding to c.2452A) and the reference C (corresponding to c.2452G)
region of the mutation. The E818K mutation found in all three CAPOS
tation, which is associated with alternating hemiplegia of childhood, is
y conserved.
Demos et al. Orphanet Journal of Rare Diseases 2014, 9:15 Page 3 of 9
http://www.ojrd.com/content/9/1/15human genome reference sequence (HG18) using BWA
[3]. Duplicate reads and reads with a mapping score of
0 were removed, and the remaining aligned reads were
exported to pileup format. Variants were identified
using SAMtools [4]. We filtered out variants with a qual-
ity score below 10 at varFilter parameter −D 1000 for
single nucleotide variants and varFilter parameters −D
1000, −d 2 and − l 30 for indels. We annotated the
filtered variants as “known” or “novel”, depending on
whether they had been previously reported in dbSNP
(version 129 or 130) [5,6] or in the 1000 Genomes Project
[7,8]. We also determined how many times the variant had
previously been observed in our in-house database of 1834
normal germline genomes sequenced at Canada’s Michael
Smith Genome Sciences Centre.
Results
Table 1 provides an overview of the clinical features of
these three, apparently unrelated families. Additional
file 1: Table S1 summarizes the results of investigations
performed in the families.
Family 1
Following normal development, the male proband
(Figure 1A, Family 1 III-1) of this Caucasian United
Kingdom family experienced three episodes of lethargy,
hypotonia, and ataxia during acute febrile illnesses,
beginning at age 16 months. The most severe episode
occurred at age 4.5 years, when he was comatose for a
week. Neurologic sequelae at 6 years of age included
markedly ataxic gait, poor hand coordination, truncal
hypotonia, nystagmus, dysarthria, optic atrophy with ab-
sent visual evoked potentials and moderate bilateral sen-
sorineural deafness; the latter two features had developed
at age 3 years.
On re-examination at age 22 years, his phenotype was
slightly more severe than that described at age 6 years.
He had suffered no acute episodes since age 4.5 years
but had slow progression of all symptoms since that
time. His balance remained poor, and, although he
walked unaided, he could not walk on uneven surfaces.
He read with the assistance of an electronic magnifier
and wore hearing aids. His cognition was normal, and he
was studying at university.
His 49-year old mother (Figure 1A, Family 1 II-1) was
well until the age of 18 months when she developed
acute ataxia during a febrile illness. She experienced no
further acute episodes but has shown a progressive course
with visual impairment, deafness and loss of balance. At
age 31 years she had profound bilateral sensorineural
hearing loss, bilateral optic atrophy with horizontal nys-
tagmus, mild cerebellar ataxia, pes cavus, and absent deep
tendon reflexes. Since then, her walking has progressively
deteriorated: she cannot walk on uneven surfaces and hasrequired a walking stick for the past 2 years. She is now
registered blind and requires hearing aids for profound bilat-
eral hearing loss. Her visual evoked potentials and brainstem
auditory evoked potentials are absent. Electromyogram
showed motor unit loss and innervation changes.
The proband’s 20-year old sister (Figure 1A, Family 1
III-2) presented with an ataxic episode with marked
hypotonia, nystagmus and areflexia at age 9 months dur-
ing a non-specific febrile illness. She recovered but was
noted to have optic atrophy shortly after her acute
neurological symptoms resolved. She has not had any
subsequent ataxic episodes. She has developed sen-
sorineural deafness, but the severity is less than that
of her 22-year old brother. She can walk on uneven sur-
faces but tends to fall when running. Although registered
as partially sighted, she does not use any visual aids. She
has hearing aids for mild-moderate hearing loss. She is
also studying at university.
The proband’s mother’s parents (Figure 1A, Family 1 I-1
and I-2) both have normal neurological examinations.
There are two maternal sibs who were re-evaluated re-
cently, and are both unaffected at ages 50 and 46 years,
respectively.
Family 2
The proband of Family 2 (Figure 1A, Family 2 II-2) is
now a 14 year-old girl who was well until she developed
ataxic encephalopathy with a febrile illness at age 5
years. She had a reduced level of consciousness for the
first two weeks and slow recovery afterwards with dys-
arthria, dysphagia, dysmetria and truncal and gait ataxia.
She did not fully recover and was unable to walk without
support for one year following the episode. She has had
no further episodes, but progressive optic atrophy and
sensorineural hearing loss developed, and 9 years later
she wears hearing aids for bilateral moderate-to-severe
upsloping sensorineural hearing loss. She has bilateral
optic atrophy, horizontal end-gaze nystagmus, and 6/46
visual acuity. The patient has mild dysarthria, and,
although her gait has deteriorated and she is areflexic,
she is still able to walk unaided. She has had mild left
ventricular enlargement on cardiac evaluation since early
childhood. Her cognition was assessed to be low average
to average at age 10 years, and she has had attention and
school difficulties.
Her two siblings and father show similar features but
their clinical courses have been milder. The proband’s
older brother (Figure 1A, Family 2 II-1), who is now 15
years old, presented at 9 months of age during a febrile
illness. He had two further episodes of ataxic encephal-
opathy with febrile illnesses at 2.5 and 7 years of age;
transient limitation of abduction or adduction in one or
both eyes was also noted during these episodes. He had
mild residual balance difficulties following the episodes,
Table 1 Clinical features of 10 patients from three families with CAPOS syndrome
Family 1 (Previously
reported by Nicolaides
et al., 1996 [1])
Family 2 Family 3
Subject II-1 III-1a III-2 I-2 II-1 II-2a II-3 I-1a II-1 II-2
Current age 49 yr 22 yr 20 yr 43 yr 15 yr 14 yr 10 yr 40 yr 15 yr 11 yr
Episodes of ataxic encephalopathy and/or weakness
Age of onset 18 m 16 m 9 m 6 m 9 m 5 yr 18 m 3 yr 1 yr 3 yr
Number of episodes 1 3 1 2 3 1 1 3 3 2
Episodes triggered by febrile illness + + + + + + + + + +
Age of last episode 18 m 4 yr 9 m 4 yr 7 yr 5 yr 18 m 25 yr 18 m 5 yr
Abnormal eye movements - - - + + - + + + -
Dysphagia - - - - + - - +b - -
Seizures - - - - +c - - - - -
Symptoms present at most recent examination
Age at most recent exam 49 yr 22 yr 20 yr 42 yr 14 yr 13 yr 9 yr 39 yr 14 yr 10 yr
Cerebellar ataxia + + + + + + + + + +
Areflexia + + + + + + + + + +
Pes cavus + + - + - - - - - -
Optic atrophy + + + + + + + + + +
Sensorineural hearing loss + + + + + + + + + +
Dystonia - - - +d - - - - - -
Urinary symptoms - - - - - - - +e - -
Autonomic dysfunction - - - - - - - - - -
Cognitive dysfunction - - - - +f - - - - -
Autistic traits - - - - - - - - +g +g
Cardiac arrhythmia - - - +h - - - - - -
Abbreviations used: m, months; yr, years; +, present; -, absent or not noted.
aProband.
bMild persistent dysphagia was noted by age 32 years.
cBrief focal seizures (unilateral arm jerking) developed in association with first episode of fever and ataxic encephalopathy.
dPatient developed cervical dystonia responsive to onabotulinumtoxinA injections at age 32 years.
eUrinary urgency and frequency were noted by age 32 years.
fPatient was assessed at age 10 years for school difficulties and found to have low average to average IQ and reduced attention skills.
gSiblings II-1 and II-2 of family 3 were noted to have repetitive behaviours and social difficulties at age 10 and 4 years, respectively.
hPatient was diagnosed with Wolff-Parkinson-White syndrome at age 24 years.
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mild difficulties with tandem gait and standing on one foot.
He is areflexic but does not have pes cavus. Sensorineural
hearing loss was identified at age 7 years, but his subse-
quent audiological assessments have been stable, with a
mild upsloping sensorineural hearing loss bilaterally. He
uses an FM amplification device. He has bilateral optic disc
atrophy and horizontal nystagmus, with visual acuity of
6/15 in the right eye and 6/18 in the left eye. He has no aca-
demic difficulties. He has mild left ventricular enlargement
of the heart that has been stable since early childhood.
The proband’s younger brother (Figure 1A, Family 2
II-3), now aged 10 years, presented at 18 months of age
with an acute ataxic episode triggered by a febrile illness.
He has had no subsequent acute episodes but has mild
residual balance difficulties, minimal cerebellar ataxia,and absent reflexes. He had eye movement difficulties
during his acute episode, with a residual left intermittent
esotropia that improved with patching. He also has bilat-
eral optic disc atrophy and horizontal nystagmus, with
visual acuity of 6/15 bilaterally. He developed a moderate
upsloping bilateral sensorineural hearing loss and now
wears hearing aids. He has no academic problems.
The father (Figure 1A, Family 2 I-2), who is of French
Canadian descent, is currently 43 years of age. When he
was 6 months old, he developed fever, generalized hypo-
tonia and weakness, areflexia, vertical nystagmus, and
limited abduction of both eyes. He recovered but had a
similar episode with fever at age 4 years. Optic disc atro-
phy and sensorineural hearing loss were also identified
at that time. He now has profound sensorineural hearing
loss and has had a cochlear implant. He is legally blind.
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gait, areflexia and pes cavus. He was treated for Wolff-
Parkinson-White syndrome at age 24 years. He devel-
oped cervical dystonia with dystonic tremor at age 32
years and has benefited from onabotulinumtoxinA injec-
tions since 38 years of age. Sural nerve biopsy performed
at age 34 years revealed findings consistent with a mild-
moderate axonal neuropathy.
Family 3
The proband of Family 3 (Figure 1A, Family 3 I-1), who
lives in the United Kingdom and is of Caucasian descent,
is a 40-year old woman who presented at age 3 years
with a febrile illness and associated weakness and ataxia,
which resolved after 4 months. At age 11 years, she had
another acute episode, during which she became coma-
tose and was diagnosed with encephalitis. She made a
full intellectual recovery but was left with poor vision in
association with optic atrophy, severe bilateral sensori-
neural hearing loss and ataxia. After another febrile ill-
ness at age 25 years, she developed generalized weakness
and worsening of her hearing, vision and ataxia. Clinical
re-evaluation at age 27 years showed optic atrophy with
impaired vision (acuity 6/60 in the left eye and 6/36 in
the right eye) with pendular nystagmus in all directions
of gaze and superimposed square wave jerks. She had se-
vere bilateral sensorineural hearing loss, mild dysarthria,
moderate ataxia and absent deep tendon reflexes but no
pes cavus. Her cognition was normal. The neurological
findings were unchanged at 32 years of age, but she
reported swallowing difficulties owing to slow movement
of her lips and tongue, and increased urinary urgency
and frequency, which responded well to treatment with
oxybutynin. She had abnormal visual evoked potentials
bilaterally, but her electroretinogram was normal.
The proband’s mother died at age 50 years of “heart
problems” but was otherwise said to have enjoyed good
health; autopsy was not performed. The proband’s father
has no signs of neurologic or systemic disease.
The proband’s 15-year old daughter (Figure 1A, Family
3 II-1) was well until the age of 1 year when she pre-
sented with a febrile episode associated with generalized
weakness, floppiness and areflexia. She made a full re-
covery after 5 weeks. She developed similar, but milder,
problems following another febrile illness at the age of
18 months. At age 3 years she was found to have in-
creased latencies of her visual evoked potentials and
brain-stem auditory evoked potentials. Bilateral mild
sensorineural hearing loss was diagnosed at 7 years of
age, and optic disc pallor was noted at age 7.5 years. At
age 10 years, she had an upper respiratory infection and
developed acute onset of strabismus, which took several
weeks to resolve. Although her academic progress was
reported to be normal, repetitive behaviors and socialdifficulties resulted in a diagnosis of autism spectrum
disorder at age 10.5 years.
The proband's son (Figure 1A, Family 3 II-2), who is
now 11 years old, developed profound weakness, hypo-
tonia and areflexia during a febrile illness at age 3 years.
He recovered slowly over 6 months, but his brain stem
auditory evoked potentials were abnormal and by age
3.5 years he had optic disc pallor and visual acuity of 6/
12 in both eyes. He had an ataxic gait and was areflexic.
At age 5 years he had another acute febrile episode with
weakness, hypotonia and altered sensorium that resolved
after 3 days. Bilateral mild low frequency sensorineural
hearing loss was diagnosed at age 5.8 years and has been
stable since then. He has also been diagnosed with
autism spectrum disorder.
Genetic studies
We used whole exome sequencing to identify heterozy-
gous variants that were present in the same gene in the
probands of both Family 1 and Family 2, were rare in
the normal population, and were predicted to cause
non-synonymous changes in protein-coding regions or
to interfere with splicing. The results of this analysis are
summarized in Table 2. Candidate variants were vali-
dated using PCR and standard Sanger sequencing in all
seven affected and four unaffected members of CAPOS
Families 1 and 2.
Only one novel heterozygous missense variant was
demonstrated in all affected members of both families
and absent in the two unaffected spouses tested. This
variant, which was the same in both families (Additional
file 2: Figure S1), occurred at position 47,166,267 (C > T)
of chromosome 19 (NCBI36/HG18) and corresponds
to c.2452G > A (p.(Glu818Lys)) (Ensembl transcript
ENST00000302102, version 5)[9] in the ATP1A3 (sodium/
potassium-transporting ATPase subunit α3) gene (OMIM
182350) encoded on the opposite strand. We then analyzed
ATP1A3 by targeted Sanger sequencing in Family 3 and
demonstrated the same c.2452G >A mutation in all three
affected individuals. Figure 1B shows the ATP1A3 Sanger
sequencing results for Families 1–3.
We found the same ATP1A3 c.2452G >A mutation in all
three CAPOS families studied. This observation raised the
possibility that the mutation might exhibit a common ori-
gin through unaffected carrier antecedents. However, the
ATP1A3 c.2452G >A mutation in the affected mother (II-1)
in Family 1 was not inherited from either of her unaffected
parents (Figure 1B, Family 1 I-1 or I-2) and, therefore, must
have arisen de novo. (Non-paternity was excluded by testing
all six Family 1 members shown in Figure 1A with Illumina
OMNIExpress whole genome genotyping arrays)(Illumina,
Inc., San Diego, Calfiornia, USA).
The parents of the affected adults in Families 2 and 3
were not available for mutation testing, so we performed
Table 2 Summary statistics of whole exome sequencing in two unrelated patients with CAPOS syndrome
Family 1, subject III-1 Family 2, subject II-2
Total reads 108,841,666 104,389,738
Chastity-passed reads 103,868,186 102,337,954
Reads aligned with mapping quality ≥10 92,611,315 91,501,102
Average exome read deptha 69x 65x
Non-synonymous single nucleotide variants 10,911 11,254
Splice-site single nucleotide variants 517 524
Coding insertions/deletionsb 805/416 810/501
Non-silent variantsc not in dbSNP 129 or 130 2,259 2,209
Noveld heterozygous, autosomal variants 390 224
Genes with novel non-identical heterozygous variants in both probands 9e
Genes with novel identical heterozygous variants in both probands 3f
Variant segregating in all 10 affected family members tested in three CAPOS families ATP1A3
chr19:47,166,267C > T (hg18)g
c.2452G > Ah
p.Glu818Lys
aAverage read depth of exons annotated using Ensembl 54 (including potential PCR duplicates) calculated as (sum of the number of reads aligned per site for all
exonic sites) / (total number of exonic sites).
bSupported by ≥7 reads.
cIncludes non-synonymous single nucleotide variants, splice-site single nucleotide variants (within 2 bases of exon boundaries), and small, coding insertions and
deletions as annotated using Ensembl 54 gene models.
dNot previously reported in dbSNP129 or 130, 1000 Genomes Project, or 1834 non-cancer genomes collected in Canada’s Michael Smith Genome Sciences Centre’s
local database.
eNon-identical variants of 6 of these genes were called with sufficient quality in both probands to warrant confirmation by Sanger sequencing. Variants of the
following genes were tested but did not segregate with the disease in either family: WDR26, C12orf56, LMO7, and DNAH17. A variant of SIGLEC1 segregated as
expected in Family 2, but the variant found in Family 1 did not segregate as expected. A variant of MUC16 segregated as expected in Family 1, but neither of two
different variants of this gene found in Family 2 segregated as expected.
fOnly one of these variants (c.2452G > A of ATP1A3) was called with sufficient quality in both probands to warrant confirmation by Sanger sequencing. This variant
showed the expected segregation pattern with the disease in both families.
gLocation in hg19 is chr19:42,474,427C > T.
hAnnotation is on Ensembl transcript ENST00000302102, version 5.
Demos et al. Orphanet Journal of Rare Diseases 2014, 9:15 Page 6 of 9
http://www.ojrd.com/content/9/1/15genome-wide SNP genotyping on Illumina OMNIEx-
press arrays using standard protocols to determine the
haplotype on which the mutation arose. We found that
both families shared a region of more than 2 Mb con-
taining 35 informative SNPs surrounding the mutation
(Additional file 3: Figure S2). Although new mutations
are most likely in all three families, we cannot rule out the
possibility of a remote relationship between Families 2 and
3 with a common ancestral ATP1A3 c.2452G >A mutation
and incomplete penetrance.
The heterozygous ATP1A3 c.2452G > A variant found
in all 10 affected individuals in these three CAPOS fam-
ilies was not observed in more than 1834 unaffected
individuals who had undergone whole exome or whole
genome sequencing.
Discussion
ATP1A3 encodes the catalytic α3 subunit of Na
+/K+
ATPase, an integral membrane protein responsible for
establishing and maintaining electrochemical gradients
across the plasma membrane. The c.2452G > A mutation
substitutes a positively-charged lysine for a negatively-charged glutamate in the C-terminus cation transporting
domain of the Na+/K+ ATPase α3 protein. SIFT [10]
predicts this change to be damaging with high confi-
dence (score = 0), and Mutation Taster [11] predicts it to
be disease-causing (probability = 1.00). PhyloP [12] indi-
cates that the affected nucleotide is highly conserved
(score = 2.17), and this is also apparent by inspection of the
amino acid sequence in the altered region of the protein
(Figure 1C).
Na+/K+ ATPase uses adenosine triphosphate (ATP) to
pump Na+ ions out of cells and K+ ions into cells [13,14].
These gradients are involved in regulating neurotransmit-
ter reuptake and the electrical excitability of nerve and
muscle. In addition, Na+/K+ ATPase plays a key role in sev-
eral signal transduction pathways. We have not studied the
effect of the c.2452G >A mutation on Na+/K+ ATPase
function, but our observation of exactly the same missense
change in association with the same, extremely rare pheno-
type as a result of at least two, and probably three, separate
mutational events is consistent with a gain of function.
Studies of other characteristic phenotypes that are caused
by identical recurrent mutations of other genes have often
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function e.g., [15-17].
Although the c.2452G > A mutation has not been
reported before, different mutations of ATP1A3 are
known to cause two other autosomal dominant neuro-
logical diseases: rapid-onset dystonia-parkinsonism [18-20]
(DYT12; OMIM: 128235) and alternating hemiplegia of
childhood [21,22] (AHC; OMIM: 614820). These two dis-
orders have somewhat overlapping clinical features but
are generally considered to be distinct [22-24]. Moreover,Table 3 Comparison of clinical features in alternating hemipleg
(DYT12) and CAPOS syndrome (adapted and modified from Ro
Usual age of onset
Onset trigger
Emotional stress
Exercise
Hypo/Hyperthermia
Bathing
Alcohol
Neurological symptoms
Ataxic encephalopathy episodes
Hemiplegic episodes
Quadriplegic or paretic episodes
Dystonia
Dysarthria
Drooling
Reduced facial expression
Mutism
Rostrocaudal gradient
Ataxic gait
Bradykinesia
Seizures
Choreoathetosis
Abnormal eye movements during episodes
Areflexia
Pes cavus
Optic atrophy/visual loss
Sensorineural hearing loss
Developmental delay or intellectual disability
Clinical course
Abrupt onset
Polyphasic with slow progression of non-paroxysmal symptoms
Mono- or biphasic with slow progression of neurological symptoms
Abbreviations used: m, months; yr, years; +, feature usually occurs; +/−, feature may
aCannot assess in infancy or early childhood.
bHyperthermia only.the ATP1A3 mutations reported in the two conditions
all differ, and most alternating hemiplegia of childhood
mutations occur de novo, while rapid-onset dystonia-
parkinsonism mutations are more often inherited [21-24].
This genotype-phenotype correlation also extends to
CAPOS syndrome in that the mutation we observed has
not been seen in either of the other conditions associated
with ATP1A3 mutations, and the clinical features of
CAPOS syndrome, although somewhat overlapping, are
distinct from those of rapid-onset dystonia-parkinsonismia of childhood (AHC), rapid-onset dystonia-parkinsonism
sewich et al. [22])
Alternating hemiplegia
of childhood
Rapid-onset dystonia-
parkinsonism
CAPOS
syndrome
0 – 18 m 4 – 55 yr 6 m – 5 yr
?a + ?a
?a + ?a
+ + +b
+ Not reported -
?a + ?a
- - +
+ - -
+ - +
+ + −/+
+ + −/+
+ + −/+
−/+ + -
−/+ + -
+ + -
−/+ + +
−/+ + -
−/+ −/+ −/+
+ - -
+ −/+ −/+
- - +
- - −/+
- - +
- - +
+ −/+ −/+
+ + +
+ - −/+
- + −/+
occur; -, feature not described.
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the ATP1A3 mutations associated with DYT12 or AHC
that have been assessed functionally produce loss of func-
tion [18,20,21], while the recurrent c.2452G > A variant
found in the three CAPOS syndrome families presented
here has characteristics of a gain-of-function mutation, as
discussed above.
Table 3 provides an overview of the phenotypic simi-
larities and differences between the three conditions.
CAPOS syndrome, DYT12 and AHC all can be inherited
as autosomal dominant traits, and all three are charac-
terized by variable expressivity. All may exhibit acute
onset of neurological symptoms in childhood in associ-
ation with a febrile illness, but the predominant neuro-
logical manifestations differ – ataxic encephalopathy in
CAPOS syndrome, dystonia/parkinsonism in DYT12,
and transient episodes of hemiplegia and other symp-
toms including dystonia in AHC.
In contrast to AHC and DYT12, in which the dystonic
symptoms are often asymmetric and progress in a ros-
trocaudal gradient, dystonia is an uncommon feature in
CAPOS syndrome. The clinical features that progress in
this disorder are more generalized and symmetric; they
include progressive gait ataxia and loss of vision and
hearing. Bulbar symptoms, which typically occur in AHC
and DYT12, are uncommon in CAPOS syndrome.
Optic atrophy and sensorineural hearing loss have not
been reported in DYT12 or AHC but are frequent fea-
tures of CAPOS syndrome. These symptoms in our
patients are slowly progressive over time. The recent
demonstration that the Na+/K+-ATPase α3 subunit plays
a critical role in anchoring retinoschisin, the protein in-
volved in X-linked juvenile retinoschisis, to photorecep-
tor and bipolar cells of the retina in a mouse model is
compatible with involvement of ATP1A3 in visual function
[25]. The role of the Na+/K+-ATPase α3 subunit in hearing
is unknown, but ATP1A3 is abundantly expressed in mem-
branes of spiral ganglion somata, type I afferent terminals
contacting inner hair cells and medial efferent terminals
contacting the outer hair cells of the cochlea [26].
Unaffected carriers have been reported for other ATP1A3
missense mutations in rapid-onset dystonia-parkinsonism
[18,19,27], but there is no evidence for incomplete pene-
trance in CAPOS syndrome. We demonstrated a de novo
origin for the ATP1A3 c.2452G >A mutation in Family 1
(Figure 1B), and the clinical and family histories are most
compatible with separate, recurrent de novo mutations in
Families 2 and 3 as well.
We conclude that a heterozygous c.2452G > A muta-
tion in ATP1A3 causes CAPOS syndrome in ten affected
individuals in three different families. Clinically, CAPOS
syndrome is characterized by acute onset of ataxic enceph-
alopathy with febrile illness in childhood, partial recovery
and subsequent slow progression. Testing for ATP1A3mutations should be considered in other patients with
features of CAPOS syndrome or with other paroxysmal
and progressive forms of early-onset dystonia, weakness
or ataxia.Additional files
Additional file 1: Table S1. Investigations performed on 10 patients
from three families with CAPOS syndrome.
Additional file 2: Figure S1. Visualization of read alignments supporting
the ATP1A3 mutation in the libraries from each of the two probands. Upper
panel: Family 1 subject III-1. Lower panel: Family 2 subject II-2. Read
alignments to hg18 stored in BAM files were manually examined, and the
alignment image was exported using Integrated Genome Viewer [28,29]. The
heterozygous C > T mutation at chromosome 19:47,166,267 was corroborated
by 22 out of 41 reads in Family 1 subject III-I and by 34 out of 59 reads in
Family 2 subject II-2.
Additional file 3: Figure S2. Haplotyping results in Families 2 and 3 in
the region flanking the ATP1A3 mutation.
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